跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2023/04/051726
CTRI/2023/04/051726尚未招募1 期

A prospective, interventional, open-label, phase 1a/1b, single-center, clinical study to evaluate the safety and tolerability of NV-CoV-2 Oral Syrup and Oral Gummy (Chewable gel) for oral administration in healthy and mild to moderate COVID-19 adult human subjects.

Karveer Meditech Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
尚未招募
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •Common for healthy subjects and COVID-19 patients:
  • •1-Able to comprehend the nature and purpose of the study and willing to give written informed consent for participation in the study
  • •2-Willing to be available for the entire study period and to comply with protocol requirements.
  • •3-In the case of female subjects:
  • •a-Negative urine pregnancy test during screening and negative serum ß-hCG test at check-in of each study period.
  • •b-Female subjects with childbearing potential or those within their first two years of onset of menopause must either abstain from sexual intercourse or use acceptable methods of birth control for at least 15 days before 1st dose till 15 days post-last-dose/ entire study period [Acceptable birth control methods include barrier methods such as diaphragm/condom with or without spermicide or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed)].
  • •c-They should not be in menstruation (bleeding per vaginum) on the day of the withdrawal of blood for the purpose of the study
  • •For healthy subjects
  • •1-Normal, healthy, adult, human subject of 18 to 60 years (both inclusive) of age.
  • •2-Body mass index in the range of 18 – 30 Kg/m2 (both inclusive).
  • •3-Normal haemoglobin between 12.5 to 17.5 grams per deciliter (g/dL) for men and 11 to 16 g/dL for females or as per the discretion of PI/Physician.
  • •4-Normal health status as determined by medical history and physical examination by the PI/Physician at the time of screening and vital signs (blood pressure, pulse rate, respiratory rate and axillary temperature) measurements and physical examination at the time of screening as well as check-in during each study period.
  • •5-With normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests and urine analysis
  • •6-With a normal or clinically non-significant 12-lead ECG.
  • •7-With a negative test for Human Immunodeficiency Virus (HIV) type I/II antibodies, Hepatitis B surface antigen (HBsAg) and Hepatitis C virus (HCV) antibodies, COVID-19 RT PCR.
  • •8-Non-smokers and should not have been consuming any kind of tobacco products including chewing or inhaling tobacco in the form of jarda, pan, gutkha etc,
  • •In the case of smokers, they should be willing to abstain from smoking or chewing any tobacco-containing product for at least 72.00 hours prior to check-in of the first period and throughout the duration of the study till safety samples are collected at the end of the study.
  • •For mild to moderate Covid-19 patients
  • •1-Both male and female adult populations aged from 18 to 60 years will be included in the study.
  • •2-Confirmed RT-PCR positive for SARS CoV-2 mild to moderate (as per WHO classification) or asymptomatic patients as determined by the principal investigator/ study physician.
  • •3-Controlled Diabetes (Type 2 DM (Hb1Ac < 7) and Hypertension (Systolic BP <140 mm Hg or diastolic BP <90 mm Hg).
  • •4-Patients having risk factors of hospitalization due to Covid-19.
  • •5-Patients with BMI from =18 to = 35 kg/m2.

排除标准

  • •For healthy subjects:
  • •1-Any medical or surgical condition, which might significantly interfere with the functioning of the gastrointestinal tract or blood-forming organs.
  • •2-History or presence of gastric or duodenal ulcer or GI bleeding or blood in stools anytime in the past.
  • •3-History of severe infection or major surgery in the past 6 months.
  • •4-History of Minor surgery or fracture within the past 3 months.
  • •5-Significant history or current evidence of malignancy or chronic - infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, immunological, or psychiatric diseases, or organ dysfunction.
  • •6-Any major illness or hospitalization within 90 days prior to check-in of the first period.
  • •7-Any other clinical condition like diarrhea or vomiting within three days prior to check-in of any period.
  • •8-Subjects who have been on an unusual or abnormal diet, for whatever reason e.g. because of fasting due to religious reasons during four weeks before check-in of the first period and throughout the duration of the study until the post-study safety sample is collected.
  • •9-Use of any depot injection or an implant of any drug within three months prior to check-in of the first period and throughout the duration of the study until the post-study safety sample is collected.
  • •10-Use of any prescribed medication (including herbal medicines and vitamin supplements) within 30 days or within five half-lives of the drug, whichever is longer prior to check-in of the first period and throughout the duration of the study until the post-study safety sample is collected.
  • •11-Use of any OTC products within 7 days or within five half-lives of the drug, whichever is longer prior to first check-in and throughout the duration of the study until the post-study safety sample is collected.
  • •12-Use of any recreational drug or history of drug addiction.
  • •13-Participated in any clinical investigation requiring repeated blood sampling, blood donation, or otherwise leading to blood loss of =300 mL in the past 90 days prior to first check-in.
  • •14-Participated in any clinical study within the past 90 days prior to check-in.
  • •15-Consumption of alcohol or alcoholic products within 24.00 hrs prior to check-in in each study period and throughout sampling time points.
  • •16-Positive alcohol breath or urine screening for drug abuse tests during check-in in each study period.
  • •17-Consumption of xanthine or its derivative containing food or beverages (e.g. chocolates, tea, coffee or cola drinks) within 48.00 hours prior to check-in in each study period and throughout sampling time points.
  • •18-Consumption of grapefruit or its juice within 72.00 hours prior to check-in in each study period and throughout sampling time points.
  • •19-Pregnant, lactating or nursing female subjects.
  • •20-Female subjects using hormonal contraceptives (oral/implants).
  • •21-History of allergy or hypersensitivity or intolerance to study drugs or its formulation excipients which, in the opinion of the PI/Physician, would compromise the safety of the subject or the study.
  • •22-History of difficulty in the accessibility of veins in arms.
  • •23-Evidence of an uncooperative attitude.
  • •For mild to moderate Covid-19 patients
  • •1-If the physician as per their judgment considers the

研究者

相似试验

进行中（未招募）
1 期
The study to assess the efficacy and safety of new Interferon alpha-2b formulation in patients with primary myelofibrosisPrimary Myelofibrosis (grade MF-0 and MF-1) according to the WHO criteriaMedDRA version: 17.0 Level: LLT Classification code 10053134 Term: Osteomyelofibrosis System Organ Class: 100000004864
EUCTR2014-001367-13-ATMedizinische Universtät Wien, Universitätsklinik für Innere Medizin I24
已完成
1 期
A clinical study to assess the safety of Diptheria, Tetanus, acellular Pertussis, Poliomyelitis and Haemophilus influenzae type b vaccine in healthy adults
CTRI/2017/07/009034Serum Institute of India Pvt Ltd24
进行中（未招募）
1 期
Clinical study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiency
EUCTR2011-004154-25-DEBiotest AG36
进行中（未招募）
1 期
Clinical study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiencyPatients with congenital afibrinogenemia or severe congenital hypofibrinogenemiaMedDRA version: 20.0Level: LLTClassification code 10066356Term: Congenital hypofibrinogenaemiaSystem Organ Class: 100000004850
EUCTR2011-004154-25-BGBiotest AG36
招募中
3 期
Clinical trial on Kerala Ayurveda product in Tiredness subjects
CTRI/2022/11/047555Kerala Ayurveda Limited